Related Experiment Video
Updated: May 12, 2025

07:00
Excitotoxic Stimulation of Brain Microslices as an In vitro Model of Stroke
Published on: February 4, 2014
8.4K
Targeting the Ischemic Core: A Therapeutic Microdialytic Approach to Prevent Neuronal Death and Restore Functional
May-Jywan Tsai1,2, Dann-Ying Liou1,2, Li-Yu Fay1,2,3
1Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
International Journal of Molecular Sciences
|May 7, 2025
Summary
Therapeutic microdialysis (tMD) removes damaging glutamate and zinc ions from the ischemic stroke core. This minimally invasive method reduces brain damage and improves recovery, offering neuroprotection beyond six hours post-stroke.
Area of Science:
- Neuroscience
- Biomedical Engineering
Background:
- Ischemic stroke causes ionic imbalance, acidosis, oxidative stress, and inflammation.
- Key mediators like glutamate and zinc contribute to cell damage in the ischemic core.
Purpose of the Study:
- To develop and evaluate a minimally invasive therapeutic microdialysis (tMD) method for treating ischemic stroke.
- To assess the efficacy of tMD in removing detrimental substances and conferring neuroprotection.
Main Methods:
- Developed a minimally invasive therapeutic microdialysis (tMD) technique.
- Used a buffer containing serum albumin, an osmotic agent, perfused into the ischemic core.
- Measured the removal of glutamate and zinc ions and assessed infarct volume and neurobehavioral outcomes.
Main Results:
- tMD significantly removed glutamate and zinc ions from the ischemic core.
- Treatment reduced infarct volumes and provided significant neurobehavioral protection.
- tMD protected neurons, reduced microglial activation, and extended the therapeutic window beyond 6 hours.
Conclusions:
- Minimally invasive tMD is a feasible and effective treatment for ischemic stroke.
- tMD reduces key damaging mediators, offering neuroprotection and potentially expanding the therapeutic time window.
- This approach shows promise for clinical application in ischemic stroke patients with minimal adverse effects.

